Showing results (1-10 of 13) with videos related to
Sort By:
Pageof 2
European Journal of Pain (London, England)|October 4, 2005
The NK1-receptor antagonist TKA731 in painful diabetic neuropathy: a randomised, controlled trialSøren H Sindrup, Ana Graf, Nikolaos SfikasStatistics in Medicine|February 28, 2014
Quantifying unrecognised replication present in reports of HIV diagnosesNikolaos Sfikas, David Greenhalgh, Wenwen Huo, et al.Advances in Therapy|November 22, 2014
No evidence of disease activity: indirect comparisons of oral therapies for the treatment of relapsing-remitting multiple sclerosisRichard Nixon, Niklas Bergvall, Davorka Tomic, et al.Gender Medicine|August 18, 2009
Effects of gender on response to treatment with rivastigmine in mild cognitive impairment: A post hoc statistical modeling approachSteven Ferris, Roger Lane, Nikolaos Sfikas, et al.Multiple Sclerosis (Houndmills, Basingstoke, England)|May 10, 2014
The influence of patient demographics, disease characteristics and treatment on brain volume loss in Trial Assessing Injectable Interferon vs FTY720 Oral in Relapsing-Remitting Multiple Sclerosis (TRANSFORMS), a phase 3 study of fingolimod in multiple sclerosisFrederik Barkhof, Remko de Jong, Nikolaos Sfikas, et al.Biometrical Journal. Biometrische Zeitschrift|August 23, 2023
Opportunities and challenges with decentralized trials in NeuroscienceHans Ulrich Burger, Tom Van de Casteele, Khadija Rerhou Rantell, et al.Journal of Clinical Pharmacology|April 14, 2010
Sotrastaurin and tacrolimus coadministration: effects on pharmacokinetics and biomarker responsesJohn M Kovarik, Sylvie Stitah, Alan Slade, et al.Biopharmaceutics & Drug Disposition|June 26, 2010
Sotrastaurin and cyclosporine drug interaction study in healthy subjectsJohn M Kovarik, Sylvie Stitah, Alan Slade, et al.Therapeutic Innovation & Regulatory Science|February 5, 2024
Decentralized Clinical Trials: Scientific Considerations Through the Lens of the Estimand FrameworkRima Izem, Emmanuel Zuber, Nadia Daizadeh, et al.Journal of Neurology|September 5, 2015
Long-term results from a phase 2 extension study of fingolimod at high and approved dose in relapsing multiple sclerosisXavier Montalban, Giancarlo Comi, Jack Antel, et al.Pageof 2